Loading…

A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome

The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we descr...

Full description

Saved in:
Bibliographic Details
Published in:ACS chemical biology 2012-10, Vol.7 (10), p.1711
Main Authors: Disney, Matthew D, Liu, Biao, Yang, Wang-Yong, Sellier, Chantal, Tran, Tuan, Charlet-Berguerand, Nicolas, Childs-Disney, Jessica L
Format: Article
Language:English
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 10
container_start_page 1711
container_title ACS chemical biology
container_volume 7
creator Disney, Matthew D
Liu, Biao
Yang, Wang-Yong
Sellier, Chantal
Tran, Tuan
Charlet-Berguerand, Nicolas
Childs-Disney, Jessica L
description The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.
doi_str_mv 10.1021/cb300135h
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_22948243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>22948243</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3</originalsourceid><addsrcrecordid>eNo1j8FKAzEURYMgtlYX_oBk2S5Gk7ykM7MsRatQcKPgrrwkb9qRSWdIUmn_3oK6uptzDlzG7qR4kELJR2dBCAlmd8HG0hhdVDWUI3ad0pcQGuZVfcVGStW6UhrGLCx4Cth1PPQduUNHPO8w84xxSznxOF2uVrMpHYcZx73nbRhi_02Je2rInYF2z5uI2_YsfhaYUu9azOR5jhT6yDHjsUWeTnsf-0A37LLBLtHt307Yx_PT-_KlWL-tXpeLdTFINc-FNs47DaUjbEoyoJpKGgGkfO2l0hKh9PUc0VpTCQJZG0sWrFMSnDLoYcLuf7vDwQbymyG2AeNp8_8bfgAVb1h1</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</creator><creatorcontrib>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</creatorcontrib><description>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</description><identifier>EISSN: 1554-8937</identifier><identifier>DOI: 10.1021/cb300135h</identifier><identifier>PMID: 22948243</identifier><language>eng</language><publisher>United States</publisher><subject>Animals ; Ataxia - drug therapy ; Binding, Competitive - drug effects ; Cell Nucleus - drug effects ; Cercopithecus aethiops ; COS Cells ; Fragile X Syndrome - drug therapy ; Protein Binding ; Repetitive Sequences, Nucleic Acid - drug effects ; RNA - drug effects ; RNA Splicing ; Small Molecule Libraries ; Tremor - drug therapy</subject><ispartof>ACS chemical biology, 2012-10, Vol.7 (10), p.1711</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27898,27899</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22948243$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Disney, Matthew D</creatorcontrib><creatorcontrib>Liu, Biao</creatorcontrib><creatorcontrib>Yang, Wang-Yong</creatorcontrib><creatorcontrib>Sellier, Chantal</creatorcontrib><creatorcontrib>Tran, Tuan</creatorcontrib><creatorcontrib>Charlet-Berguerand, Nicolas</creatorcontrib><creatorcontrib>Childs-Disney, Jessica L</creatorcontrib><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><title>ACS chemical biology</title><addtitle>ACS Chem Biol</addtitle><description>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</description><subject>Animals</subject><subject>Ataxia - drug therapy</subject><subject>Binding, Competitive - drug effects</subject><subject>Cell Nucleus - drug effects</subject><subject>Cercopithecus aethiops</subject><subject>COS Cells</subject><subject>Fragile X Syndrome - drug therapy</subject><subject>Protein Binding</subject><subject>Repetitive Sequences, Nucleic Acid - drug effects</subject><subject>RNA - drug effects</subject><subject>RNA Splicing</subject><subject>Small Molecule Libraries</subject><subject>Tremor - drug therapy</subject><issn>1554-8937</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><recordid>eNo1j8FKAzEURYMgtlYX_oBk2S5Gk7ykM7MsRatQcKPgrrwkb9qRSWdIUmn_3oK6uptzDlzG7qR4kELJR2dBCAlmd8HG0hhdVDWUI3ad0pcQGuZVfcVGStW6UhrGLCx4Cth1PPQduUNHPO8w84xxSznxOF2uVrMpHYcZx73nbRhi_02Je2rInYF2z5uI2_YsfhaYUu9azOR5jhT6yDHjsUWeTnsf-0A37LLBLtHt307Yx_PT-_KlWL-tXpeLdTFINc-FNs47DaUjbEoyoJpKGgGkfO2l0hKh9PUc0VpTCQJZG0sWrFMSnDLoYcLuf7vDwQbymyG2AeNp8_8bfgAVb1h1</recordid><startdate>20121019</startdate><enddate>20121019</enddate><creator>Disney, Matthew D</creator><creator>Liu, Biao</creator><creator>Yang, Wang-Yong</creator><creator>Sellier, Chantal</creator><creator>Tran, Tuan</creator><creator>Charlet-Berguerand, Nicolas</creator><creator>Childs-Disney, Jessica L</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20121019</creationdate><title>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</title><author>Disney, Matthew D ; Liu, Biao ; Yang, Wang-Yong ; Sellier, Chantal ; Tran, Tuan ; Charlet-Berguerand, Nicolas ; Childs-Disney, Jessica L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Animals</topic><topic>Ataxia - drug therapy</topic><topic>Binding, Competitive - drug effects</topic><topic>Cell Nucleus - drug effects</topic><topic>Cercopithecus aethiops</topic><topic>COS Cells</topic><topic>Fragile X Syndrome - drug therapy</topic><topic>Protein Binding</topic><topic>Repetitive Sequences, Nucleic Acid - drug effects</topic><topic>RNA - drug effects</topic><topic>RNA Splicing</topic><topic>Small Molecule Libraries</topic><topic>Tremor - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Disney, Matthew D</creatorcontrib><creatorcontrib>Liu, Biao</creatorcontrib><creatorcontrib>Yang, Wang-Yong</creatorcontrib><creatorcontrib>Sellier, Chantal</creatorcontrib><creatorcontrib>Tran, Tuan</creatorcontrib><creatorcontrib>Charlet-Berguerand, Nicolas</creatorcontrib><creatorcontrib>Childs-Disney, Jessica L</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>ACS chemical biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Disney, Matthew D</au><au>Liu, Biao</au><au>Yang, Wang-Yong</au><au>Sellier, Chantal</au><au>Tran, Tuan</au><au>Charlet-Berguerand, Nicolas</au><au>Childs-Disney, Jessica L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome</atitle><jtitle>ACS chemical biology</jtitle><addtitle>ACS Chem Biol</addtitle><date>2012-10-19</date><risdate>2012</risdate><volume>7</volume><issue>10</issue><spage>1711</spage><pages>1711-</pages><eissn>1554-8937</eissn><abstract>The development of small molecule chemical probes or therapeutics that target RNA remains a significant challenge despite the great interest in such compounds. The most significant barrier to compound development is defining which chemical and RNA motif spaces interact specifically. Herein, we describe a bioactive small molecule probe that targets expanded r(CGG) repeats, or r(CGG)(exp), that causes Fragile X-associated Tremor Ataxia Syndrome (FXTAS). The compound was identified by using information on the chemotypes and RNA motifs that interact. Specifically, 9-hydroxy-5,11-dimethyl-2-(2-(piperidin-1-yl)ethyl)-6H-pyrido[4,3-b]carbazol-2-ium binds the 5'CGG/3'GGC motifs in r(CGG)(exp) and disrupts a toxic r(CGG)(exp)-protein complex in vitro. Structure-activity relationship studies determined that the alkylated pyridyl and phenolic side chains are important chemotypes that drive molecular recognition of r(CGG)(exp). Importantly, the compound is efficacious in FXTAS model cellular systems as evidenced by its ability to improve FXTAS-associated pre-mRNA splicing defects and to reduce the size and number of r(CGG)(exp)-containing nuclear foci. This approach may establish a general strategy to identify lead ligands that target RNA while also providing a chemical probe to dissect the varied mechanisms by which r(CGG)(exp) promotes toxicity.</abstract><cop>United States</cop><pmid>22948243</pmid><doi>10.1021/cb300135h</doi></addata></record>
fulltext fulltext
identifier EISSN: 1554-8937
ispartof ACS chemical biology, 2012-10, Vol.7 (10), p.1711
issn 1554-8937
language eng
recordid cdi_pubmed_primary_22948243
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Animals
Ataxia - drug therapy
Binding, Competitive - drug effects
Cell Nucleus - drug effects
Cercopithecus aethiops
COS Cells
Fragile X Syndrome - drug therapy
Protein Binding
Repetitive Sequences, Nucleic Acid - drug effects
RNA - drug effects
RNA Splicing
Small Molecule Libraries
Tremor - drug therapy
title A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-25T19%3A44%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20small%20molecule%20that%20targets%20r(CGG)(exp)%20and%20improves%20defects%20in%20fragile%20X-associated%20tremor%20ataxia%20syndrome&rft.jtitle=ACS%20chemical%20biology&rft.au=Disney,%20Matthew%20D&rft.date=2012-10-19&rft.volume=7&rft.issue=10&rft.spage=1711&rft.pages=1711-&rft.eissn=1554-8937&rft_id=info:doi/10.1021/cb300135h&rft_dat=%3Cpubmed%3E22948243%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p126t-45cdc437ceaf7e532f81503e2d9d1241a37d96aabb580e3195beb3bc213c25ad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/22948243&rfr_iscdi=true